

Haematologica
HAEMATOL/2018/193615
Version 3

Real world outcomes and management strategies for
venetoclax-treated chronic lymphocytic leukemia patients in the United
States

Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, and Chadi Nabhan

Disclosures: A.R.M. has served as an advisor to Abbvie, TG Therapeutics, Acerta, Janssen, Pharmacyclics, Gilead, Celgene and has research support from TG Therapeutics, Regeneron, DTRM BioPharma, Pharmacyclics, Sunesis, and Abbvie; J.A. has served on advisory boards for Genentech and Abbvie; D.M.B. has served as a consultant to Abbvie, Genentech, Novartis, Teva, Pharmacyclics, and TG Therapeutics; J.M.P. consults for Gilead Sciences, TG Therapeutics, and Pharmacyclics; C.S.U. serves on the speaker's bureau, receives research support, and consults for Abbvie and receives research funding from Pharmacyclics; B.T.H. has served on advisory boards Abbvie, Genentech, Pharmacyclics, and Gilead; R.J. serves on the speaker's bureau for Genentech and Pharmacyclics, serves on the advisory board for Gilead, receives research funding from Pharmacyclics and TG Therapeutics, and has an honorarium from TG Therapeutics; M.S. serves on the advisory boards for Abbvie and Genentech and consults for Genentech; A.P.S. serves on the advisory boards of Abbvie, Seattle Genetics, and Pharmacyclics and is a member of the speaker's bureaus for Abbvie, Genentech, Seattle Genetics, Novartis, and Gilead Sciences; P.M.B. consults for Abbvie; J.S. consults for Bristol Meyer Squibb, Seattle Genetics, and Kite and receives research funding from Merck, Bristol Meyer Squibb, Seattle Genetics, Celgene, and Pharmacyclics; R.R.F. consults for Abbvie. A.G., C.G, M.T., N.L., F.L., J.J.P., A.R.S., B.D.C, C.S.Z., H.H.T., S.J.S., P.V.P., N.N.S., A.M.W., K.K., K.I., C.D., A.K.S., L.E.R, L.G., A.W., C.H., H.W., N.A., S.K., A.S., E.T., J.R., E.B.B., N.B., B.P., T.F.B., M.Y., M.M., and C.N. declare no competing financial interests.

Contributions: A.R.M. and C.N. designed the study, collected data, and prepared the manuscript; M.T. prepared the manuscript; J.N.A., D.M.B., J.M.P., C.S.U., N.L., B.T.H., N.L., F.L., R.J., M.S., A.P.S., J.J.P., P.M.B., A.R.S., B.D.C., C.S.Z., H.H.T., S.J.S., P.V.P., S.N.S., A.M.W., K.K., K.I., C.D., A.K.S., A.W., C.H., H.W., N.A., S.K., A.S., E.T., J.R., J.F., N.B., B.P., T.F.B., M.Y., M.M., J.S., R.R.F., and C.N, C.G. collected data and reviewed the manuscript; A.G., A.Z., L.E.R. and L.G. reviewed the manuscript and provided academic input.